TP53 and cancer: Other approved drugs that might be repurposed for targeting mutant p53 are metformin, proteasome inhibitors, and PARP inhibitors, which are approved for the treatment of type 2 diabetes mellitus, multiple myeloma, and BRCA-mutated cancers, respectively [11].